Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
Tuesday 05 October 2021 1:28 pm  |  Updated:  Friday 29 October 2021 3:38 pm

Covid protection from Pfizer vaccine drops to 47 per cent six months after second dose

By: Michiel Willems

Add as a preferred source on Google

The effectiveness of the Pfizer/BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47 per cent from 88 per cent six months after the second dose, according to data published that U.S. health agencies considered when deciding on the need for booster shots. Watch the full report.

[brid video=”876391″ player=”24372″ title=”Pfizer%20vaccine%20less%20effective%20after%206%20months%20study” duration=”90″ description=”The effectiveness of the Pfizer Inc/BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47% from 88% six months after the second dose, according to data published on Monday that U.S. health agencies considered when deciding on the need for booster shots. Gloria Tso reports.” uploaddate=”2021-10-05″ thumbnailurl=”//cdn.brid.tv/live/partners/18445/thumb/876391_t_1633431996.png” contentUrl=”//cdn.brid.tv/live/partners/18445/sd/876391.mp4″]

Read more

Regulator wins decade-long pricing tussle with Pfizer

Hikma reported a jump in profit for 2024

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Pharmaceuticals

Trending Articles

  • Revealed: Secret Treasury plan to tax State Pension before it is paid out

  • Two solicitors linked to Post Office scandal charged with misconduct

  • Burnham’s new chief of staff ran City firm advising Thames Water and rival Heathrow bidder

  • Barclays and Lloyds join banking sector plan for digital ID

  • Clarkson’s Farm and why businesses must stop blaming the weather

More from City PM

  • Regulator wins decade-long pricing tussle with Pfizer

    Legal
    Hikma reported a jump in profit for 2024
  • Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera

    Business Wire
  • Alphabet to join Dow Jones in rare index reshuffle

    Tech
    Googles modern Kings Cross headquarters showcasing innovative architecture in Londons dynamic tech district
  • Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

    Business Wire
  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire
  • Motor finance revs up City watchdog’s PR spend

    Regulation
    Close Brothers has been swallowed up in the motor finance saga.
  • Is Zack Polanski’s honeymoon over? 

    Politics
    Zack Polanski speaking at a podium during a press conference, wearing a suit, with a cityscape backdrop and attentive audi...
  • Neo4j Acquires GraphAware to Launch Intelligence Analysis Alternative to Palantir Gotham

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy